Skip to main content

IMMUTEP Ltd

corporate_fare Company Profile

IMMUTEP Ltd

IMMP·NASDAQ·Life Sciences·CIK 0001506184

Immutep Limited is a late-stage biotechnology company that develops new immunotherapies related to Lymphocyte Activation Gene-3 (LAG-3) for cancer and autoimmune diseases. The company was incorporated in Australia on May 21, 1987, initially as a mining company called Prima Resources, and began public trading on the Australian Stock Exchange in 1988. In 2001, it transitioned into a biotechnology company after acquiring development rights for technologies from the Austin Research Institute. In December 2014, Immutep acquired Immutep S.A., a private French company, which subsequently became Immutep S.A.S. In November 2017, the company, then known as Prima BioMed Ltd, changed its name to Immutep Limited to reflect its strategic focus on developing its portfolio of LAG-3 based immunotherapy assets. Immutep's product portfolio utilizes LAG-3's ability to modulate the body's immune response. The company's registered office is located at Level 32, Australia Square, 264 George Street, Sydney 2000 New South Wales, Australia.

IMMUTEP Ltd (NASDAQ:IMMP) is a publicly traded company in the Life Sciences sector. Wiseek monitors IMMP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Immutep Reports Positive Interim Phase I Data for Autoimmune Candidate IMP761
  • Eftilagimod Alfa Linked to Significant Overall Survival in Late-Stage Cancer Patients
  • Immutep Discontinues Phase III Lung Cancer Trial, Faces $10M Partner Payment
  • Immutep's Eftilagimod Alfa Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma
  • Immutep's Eftilagimod Alfa Secures FDA Orphan Drug Designation for Soft Tissue Sarcoma

Financial Snapshot

Fiscal year ended June 30, 2025
Revenue
AU$10.33M AUD
Net Income
-AU$61.43M AUD
Diluted EPS
-AU$0.04 AUD
Op. Cash Flow
-AU$62.05M AUD
Free Cash Flow
-AU$62.1M AUD
Cash & Equivalents
AU$67.41M AUD
Debt / Equity
0.00×
Net Margin
-5.95×
Source: 20-F · filed 2025-10-24 · accession 0001193125-25-249346

Insider Transactions

IMMP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with I →
$0.3618 -0.00% today
52-week range · as of 2026-06-05 $0.2928 – $3.53
Market cap
$48.81M
Volume
395.1K (0.4× avg)
3-mo avg 992K
Live data · 2026-06-14 03:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IMMP - Latest Insights

IMMP
Jun 04, 2026, 8:27 PM EDT
Filing Type: 6-K
Importance Score:
7
Immutep Reports Positive Interim Phase I Data for Autoimmune Candidate IMP761
Price at Filing: $0.3862
Real-time Price: $0.361755 info
Change: -$0.024445 (-6%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
May 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Eftilagimod Alfa Linked to Significant Overall Survival in Late-Stage Cancer Patients
Price at Filing: $0.4268
Real-time Price: $0.361755 info
Change: -$0.065045 (-15%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
May 01, 2026, 3:57 PM EDT
Filing Type: 6-K
Importance Score:
9
Immutep Discontinues Phase III Lung Cancer Trial, Faces $10M Partner Payment
Price at Filing: $0.4389
Real-time Price: $0.361755 info
Change: -$0.077145 (-18%) info
Market Cap: $48.814M info
Sentiment: Negative
View Wiseek Article
IMMP
Apr 15, 2026, 8:42 PM EDT
Filing Type: 6-K
Importance Score:
7
Immutep's Eftilagimod Alfa Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma
Price at Filing: $0.5578
Real-time Price: $0.361755 info
Change: -$0.196045 (-35%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
Apr 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Immutep's Eftilagimod Alfa Secures FDA Orphan Drug Designation for Soft Tissue Sarcoma
Price at Filing: $0.7739
Real-time Price: $0.361755 info
Change: -$0.412145 (-53%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
Mar 19, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Immutep's Autoimmune Drug IMP761 Completes Phase I SAD with Positive Safety, Immunosuppressive Effect
Price at Filing: $0.420
Real-time Price: $0.361755 info
Change: -$0.058245 (-14%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
Mar 16, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
9
Immutep Discontinues Phase III NSCLC Trial Due to Futility Analysis
Price at Filing: $0.492
Real-time Price: $0.361755 info
Change: -$0.130245 (-26%) info
Market Cap: $48.814M info
Sentiment: Negative
View Wiseek Article
IMMP
Feb 25, 2026, 8:49 PM EST
Filing Type: 6-K
Importance Score:
9
Half-Year Report Reveals Strong Cash Position and Clinical Momentum, Bolstered by Dr. Reddy's Upfront Payment
Price at Filing: $2.79
Real-time Price: $0.361755 info
Change: -$2.43 (-87%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
Feb 09, 2026, 6:50 PM EST
Filing Type: 6-K
Importance Score:
7
Immutep Achieves 50% Enrollment in Pivotal Phase III Lung Cancer Trial
Price at Filing: $2.68
Real-time Price: $0.361755 info
Change: -$2.32 (-87%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article
IMMP
Jan 29, 2026, 7:49 PM EST
Filing Type: 6-K
Importance Score:
9
Immutep Secures A$30M Upfront Payment in Major Licensing Deal, Extends Cash Runway
Price at Filing: $3.00
Real-time Price: $0.361755 info
Change: -$2.64 (-88%) info
Market Cap: $48.814M info
Sentiment: Positive
View Wiseek Article